임상시험수탁기관(CRO) 서비스 시장 : 유형별, 제공 모델별, 모달리티별, 치료 분야별, 최종사용자별, 지역별 - 세계 예측(-2031년)

The contract research organization (CRO) services market is expected to reach USD 140.32 billion in 2031 from USD 93.02 billion in 2026, at a CAGR of 8.6% during the forecast period. The key factors contributing to market growth include the expanding pipeline of cell & gene therapies and the growing focus on precision medicine. These factors are expected to drive sponsors toward CRO partners that can handle complex designs, genomic screening, customizable logistics, and mandatory long-term follow-up capabilities that are challenging to implement in-house.

Precision programs fragment patient cohorts and shorten enrollment windows, making integrated CRO-lab networks and global site coverage decisive for timelines and data quality. As regulators and payers demand robust, real-time evidence, sponsors increasingly depend on CROs that offer clinical operations with advanced lab, data science, and RWE capabilities to de-risk development.

By service type, the early phase development services segment accounted for the second-largest share of the CRO services market in 2025.

Based on service type, the CRO services market is segmented into clinical research, early-phase development, laboratory, consulting, and data management services. In 2025, the early phase development services segment accounted for the second-largest share of the market. The current pipeline is focused on developing novel biologics, CGT, and targeted modalities that require specialized toxicology, DMPK, bioanalysis, and safety pharmacology, which several sponsors prefer to outsource to reach the IND (investigational new drug) stage faster.

By end user, the pharmaceutical & biopharmaceutical companies accounted for the largest share in the CRO services market in 2025.

Based on end user, the CRO services market is segmented into pharmaceutical & biopharmaceutical companies, medical device companies, and academic institutes. In 2025, the pharmaceutical & biopharmaceutical companies segment accounted for the largest share of the CRO services market. The large share of this end-user segment can be attributed to the large number of drug pipeline products of pharma and biotech companies. Moreover, CROs deliver speed, scale, and flexible cost bases, attracting end users.

By region, North America accounted for the largest share of the market in 2025.

In 2025, North America held the largest share of the global CRO services market, driven by the presence of well-established pharmaceutical and biotechnology industries, which drive significant demand for outsourced research and development services. Additionally, a vast network of clinical sites, hospitals, and specialized facilities provides an ideal infrastructure for conducting large-scale clinical trials in the region. Additionally, the rapid adoption of digital health solutions and decentralized trial models in the US, a significant contributor to the region's substantial share, is further boosting CRO demand, as sponsors seek innovative ways to improve patient recruitment and retention.

List of Companies Profiled in the Report:

• IQVIA Inc. (US)
• ICON plc (Ireland)
• Thermo Fisher Scientific Inc. (US)
• Laboratory Corporation of America Holdings (LabCorp) (US)
• Fortrea, Inc. (US)
• Syneos Health (US)
• WuXi AppTec (China)
• Charles River Laboratories (US)
• PAREXEL International Corporation (US)
• Pharmaron (China)
• Medpace (US)
• SGS SA (Switzerland), Frontage Labs (US)
• Eurofins Scientific (Luxembourg)
• BioAgile (India)
• Firma Clinical Research (US)
• Acculab Life Sciences (US)
• Novotech (Australia)
• KCR S.A. (US)
• Linical (Japan)
• Advanced Clinical (US)
• Allucent (US)
• Clinical Trial Service (Netherlands)
• Guires Inc. (Pepgra Healthcare Pvt. Ltd.) (UK)
• Worldwide Clinical Trials (US)
• CTI Clinical Trial And Consulting (US)

Research Coverage

This research report categorizes the CRO services market by type (clinical research services, early-phase development services, laboratory services, consulting services, and data management services), modality (small molecules, biologics, biosimilars, medical devices), delivery model (Full-service outsourcing (FSO) model, Functional service provider (FSP) model, Hybrid model), end user (pharmaceutical & biopharmaceutical companies, medical device companies, and academic institutes), and region (North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa). The report covers detailed information regarding the leading factors, such as drivers, restraints, challenges, and opportunities, influencing the growth of the CRO services market. A thorough analysis of the key industry players has provided insights into their business overview, services, key strategies, collaborations, partnerships, and agreements. New launches, collaborations, partnerships, and acquisitions are the recent developments associated with the CRO services market.

Key Benefits of Buying the Report

The report will help market leaders/new entrants by providing the closest approximations of the revenue numbers for the overall CRO services market and its subsegments. It will also help stakeholders better understand the competitive landscape and gain more insights to position their business more effectively and develop suitable go-to-market strategies. This report will enable stakeholders to understand the market's pulse and provide information on key market drivers, opportunities, and challenges.

The report provides insights into the following pointers:

• Analysis of key drivers (increasing focus on decentralized trials, rising complexity and volume of trials, service flexibility offered by CROs), opportunities (regulatory focus on patient pool diversity), and challenges (challenges of patient retention and cybersecurity/intellectual property concerns) influencing the growth of the market.
• Service Development/Innovation: Detailed insights on newly launched services of the CRO services market
• Market Development: Comprehensive information about lucrative markets - the report analyzes the market across varied regions.
• Market Diversification: Exhaustive information about new services, untapped geographies, recent developments, and investments in the CRO services market
• Competitive Assessment: In-depth assessment of market shares, growth strategies, and service offerings of key players, including IQVIA Inc. (US), ICON Plc (Ireland), Medpace (US), Laboratory Corporation of America Holdings (LabCorp) (US), Thermo Fisher Scientific Inc. (US), and Fortrea, Inc. (US). A detailed analysis of the key industry players has been conducted to provide insights into their key strategies, service launches, acquisitions, partnerships, agreements, collaborations, expansions, other recent developments, investment and funding activities, brand/service comparative analysis, and vendor valuation and financial metrics of the CRO services market

TABLE OF CONTENTS

1 INTRODUCTION

• 1.1 STUDY OBJECTIVES
• 1.2 MARKET DEFINITION
• 1.3 STUDY SCOPE
  • 1.3.1 MARKET SEGMENTATION AND REGIONAL SCOPE
  • 1.3.2 INCLUSIONS AND EXCLUSIONS
  • 1.3.3 YEARS CONSIDERED
  • 1.3.4 CURRENCY CONSIDERED
• 1.4 STAKEHOLDERS
• 1.5 SUMMARY OF CHANGES

2 EXECUTIVE SUMMARY

• 2.1 KEY INSIGHTS AND MARKET HIGHLIGHTS
• 2.2 KEY MARKET PARTICIPANTS: SHARE INSIGHTS AND STRATEGIC DEVELOPMENTS
• 2.3 DISRUPTIVE TRENDS SHAPING THE MARKET
• 2.4 HIGH-GROWTH SEGMENTS & EMERGING FRONTIERS
• 2.5 SNAPSHOT: GLOBAL MARKET SIZE, GROWTH RATE, AND FORECAST

3 PREMIUM INSIGHTS

• 3.1 GLOBAL CRO SERVICES MARKET SNAPSHOT
• 3.2 NORTH AMERICA: CRO SERVICES MARKET, BY MODALITY AND COUNTRY, 2024
• 3.3 CRO SERVICES MARKET: GEOGRAPHIC GROWTH OPPORTUNITIES

4 MARKET OVERVIEW

• 4.1 INTRODUCTION
• 4.2 MARKET DYNAMICS
  • 4.2.1 DRIVERS
    • 4.2.1.1 Rising trial volume and complexity
    • 4.2.1.2 Growing focus on decentralized/patient-centric trials
    • 4.2.1.3 Service flexibility offered by CROs
    • 4.2.1.4 Technological integrations
    • 4.2.1.5 Growing R&D investments and presence of a robust clinical pipeline
  • 4.2.2 OPPORTUNITIES
    • 4.2.2.1 Growing regulatory stringency on the diversity of the patient pool
    • 4.2.2.2 Risk-based monitoring (RBM) and risk-based quality management as a service
    • 4.2.2.3 Offering data analysis outcomes favoring clients' reimbursement and market access strategy
    • 4.2.2.4 AI-powered clinical development and decentralized trial models
  • 4.2.3 CHALLENGES
    • 4.2.3.1 Patient retention
    • 4.2.3.2 Cybersecurity or intellectual property challenges
• 4.3 UNMET NEEDS AND WHITE SPACES
• 4.4 INTERCONNECTED MARKETS AND CROSS-SECTOR OPPORTUNITIES
• 4.5 STRATEGIC MOVES BY TIER-1/2/3 PLAYERS

5 INDUSTRY TRENDS

• 5.1 MARKET TRENDS
  • 5.1.1 INTEGRATION OF HEOR AND RWE INTO CLINICAL TRIAL DESIGN
  • 5.1.2 IN SILICO TRIALS
  • 5.1.3 SPECIALIZED BIOANALYTICS FOR EMERGING MODALITIES (CGT)
• 5.2 PORTER'S FIVE FORCES ANALYSIS
  • 5.2.1 THREAT OF NEW ENTRANTS
  • 5.2.2 THREAT OF SUBSTITUTES
  • 5.2.3 BARGAINING POWER OF BUYERS
  • 5.2.4 BARGAINING POWER OF SUPPLIERS
  • 5.2.5 INTENSITY OF COMPETITIVE RIVALRY
• 5.3 MACROECONOMIC OUTLOOK
  • 5.3.1 INTRODUCTION
  • 5.3.2 GDP TRENDS AND FORECAST
  • 5.3.3 TRENDS IN GLOBAL CRO SERVICES MARKET
• 5.4 VALUE CHAIN ANALYSIS
• 5.5 ECOSYSTEM ANALYSIS
• 5.6 PRICING ANALYSIS
  • 5.6.1 INDICATIVE PRICING RANGE, BY SERVICE TYPE, 2025
  • 5.6.2 INDICATIVE PRICING ANALYSIS, BY PHASE, 2025
  • 5.6.3 INDICATIVE PRICING ANALYSIS, BY REGION, 2025
• 5.7 KEY CONFERENCES & EVENTS, 2026-2027
• 5.8 TRENDS/DISRUPTIONS IMPACTING CUSTOMERS' BUSINESSES
• 5.9 INVESTMENT AND FUNDING SCENARIO
• 5.10 IMPACT OF 2025 US TARIFFS-CRO SERVICES MARKET
  • 5.10.1 INTRODUCTION
  • 5.10.2 KEY TARIFF RATES
  • 5.10.3 PRICE IMPACT ANALYSIS
  • 5.10.4 IMPACT ON COUNTRIES/REGIONS
    • 5.10.4.1 North America
      • 5.10.4.1.1 US
    • 5.10.4.2 Europe
    • 5.10.4.3 Asia Pacific
  • 5.10.5 IMPACT ON END-USE INDUSTRIES
    • 5.10.5.1 Pharmaceutical & biotech companies
    • 5.10.5.2 Medical device companies
    • 5.10.5.3 Academic institutes

6 TECHNOLOGICAL ADVANCEMENTS, AI-DRIVEN IMPACT, INNOVATIONS, AND FUTURE APPLICATIONS

• 6.1 KEY TECHNOLOGIES
  • 6.1.1 AI-INTEGRATED CLINICAL TRIAL MANAGEMENT SYSTEM (CTMS) & ELECTRONIC TRIAL MASTER FILE (ETMF) PLATFORMS
  • 6.1.2 RANDOMIZATION AND TRIAL SUPPLY MANAGEMENT (RTSM)
  • 6.1.3 ELECTRONIC DATA CAPTURE (EDC) SYSTEM
• 6.2 COMPLEMENTARY TECHNOLOGIES
  • 6.2.1 DIGITAL BIOMARKERS, WEARABLES & ELECTRONIC PATIENT-REPORTED OUTCOME (EPRO) TOOLS
  • 6.2.2 MODEL-INFORMED DRUG DEVELOPMENT (MIDD)
  • 6.2.3 DATA MANAGEMENT AND INFORMATICS TECHNOLOGIES
  • 6.2.4 REAL-WORLD EVIDENCE (RWE) & REAL-WORLD DATA (RWD) PLATFORMS
• 6.3 ADJACENT TECHNOLOGIES
  • 6.3.1 CLINICAL TRIAL SIMULATION TOOLS
• 6.4 TECHNOLOGY/SERVICE ROADMAP
• 6.5 FUTURE APPLICATIONS
• 6.6 IMPACT OF AI/GEN AI ON CRO SERVICES MARKET
  • 6.6.1 INTRODUCTION
  • 6.6.2 MARKET POTENTIAL ACROSS DRUG DEVELOPMENT STAGES
  • 6.6.3 AI USE CASES
  • 6.6.4 FUTURE OF GENERATIVE AI IN DRUG DEVELOPMENT ECOSYSTEM

7 REGULATORY LANDSCAPE AND SUSTAINABILITY INITIATIVES

• 7.1 REGIONAL REGULATIONS AND COMPLIANCE
  • 7.1.1 REGULATORY BODIES, GOVERNMENT AGENCIES, AND OTHER ORGANIZATIONS
  • 7.1.2 INDUSTRY STANDARDS
    • 7.1.2.1 North America
    • 7.1.2.2 Europe
    • 7.1.2.3 Asia Pacific
    • 7.1.2.4 Rest of the World
  • 7.1.3 CERTIFICATIONS, LABELING, & ECO-STANDARDS
  • 7.1.4 REGULATORY ANALYSIS
  • 7.1.5 REGULATORY SCENARIO FOR DRUG APPROVALS AND CGMP PROCEDURES
• 7.2 SUSTAINABILITY INITIATIVES

8 CUSTOMER LANDSCAPE & BUYER BEHAVIOR

• 8.1 DECISION-MAKING PROCESS
• 8.2 KEY STAKEHOLDERS INVOLVED IN BUYING PROCESS AND THEIR EVALUATION CRITERIA
  • 8.2.1 KEY STAKEHOLDERS IN BUYING PROCESS
  • 8.2.2 BUYING CRITERIA
• 8.3 CUSTOMER LANDSCAPE
  • 8.3.1 BUDGET ALLOCATION TREND
  • 8.3.2 ADOPTION BARRIERS & INTERNAL CHALLENGES
• 8.4 UNMET NEEDS FROM VARIOUS END-USE INDUSTRIES
• 8.5 MARKET PROFITABILITY

9 CRO SERVICES MARKET, BY TYPE

• 9.1 INTRODUCTION
• 9.2 CLINICAL RESEARCH SERVICES
  • 9.2.1 PHASE III
    • 9.2.1.1 Large-scale testing ability to assess efficacy and safety of drugs to aid growth
  • 9.2.2 PHASE II
    • 9.2.2.1 Growing number of pipeline products in Phase II studies to drive market
  • 9.2.3 PHASE I
    • 9.2.3.1 Robust pipeline of pharmaceutical and biopharmaceutical products to support growth
  • 9.2.4 PHASE IV
    • 9.2.4.1 Stringent global regulations for drug safety monitoring to spur growth
• 9.3 EARLY-PHASE DEVELOPMENT SERVICES
  • 9.3.1 CHEMISTRY, MANUFACTURING, AND CONTROLS SERVICES
    • 9.3.1.1 Growing need to meet regulatory norms for drugs to fuel market
  • 9.3.2 PRECLINICAL SERVICES
    • 9.3.2.1 Pharmacokinetics/Pharmacodynamics
      • 9.3.2.1.1 Rise in outsourcing services by pharmaceutical and biopharmaceutical companies to promote growth
    • 9.3.2.2 Toxicology testing
      • 9.3.2.2.1 Need to prevent late-stage failures to contribute to growth
    • 9.3.2.3 Other preclinical services
  • 9.3.3 DISCOVERY STUDIES
    • 9.3.3.1 Increasing reliance on CRO services for target identification and validation to expedite growth
• 9.4 LABORATORY SERVICES
  • 9.4.1 ANALYTICAL TESTING
    • 9.4.1.1 Physical characterization
      • 9.4.1.1.1 Ability to minimize product failure in late-phase development to favor growth
    • 9.4.1.2 Raw material testing
      • 9.4.1.2.1 Need to maintain quality of finished product to facilitate growth
    • 9.4.1.3 Batch-release testing
      • 9.4.1.3.1 Need to maintain batch-to-batch consistency of pharmaceutical dosage forms to advance growth
    • 9.4.1.4 Stability testing
      • 9.4.1.4.1 Ability to establish drug compatibility and formulation development to aid growth
    • 9.4.1.5 Other analytical testing services
  • 9.4.2 BIOANALYTICAL TESTING
    • 9.4.2.1 Increasing outsourcing of R&D activities to accelerate growth
• 9.5 CONSULTING SERVICES
  • 9.5.1 GROWING ADOPTION OF CONSULTING SERVICES FOR FASTER REGULATORY APPROVALS TO BOOST MARKET
• 9.6 DATA MANAGEMENT SERVICES
  • 9.6.1 NEED TO TRACK PROGRESS OF EARLY DRUG DEVELOPMENT TO AUGMENT GROWTH

10 CRO SERVICES MARKET, BY DELIVERY MODEL

• 10.1 INTRODUCTION
• 10.2 FULL-SERVICE OUTSOURCING (FSO) MODEL
  • 10.2.1 RISE IN NUMBER OF EMERGING BIOPHARMACEUTICAL COMPANIES TO DRIVE MARKET
• 10.3 FUNCTIONAL SERVICE PROVIDER (FSP) MODEL
  • 10.3.1 GROWING ADOPTION OF FSP SERVICES BY LARGE PHARMACEUTICAL COMPANIES TO FUEL MARKET GROWTH
• 10.4 HYBRID MODEL
  • 10.4.1 HIGH FLEXIBILITY OFFERED BY HYBRID MODEL TO SUPPORT MARKET GROWTH

11 CRO SERVICES MARKET, BY MODALITY

• 11.1 INTRODUCTION
• 11.2 SMALL MOLECULES
  • 11.2.1 ONGOING SURGE IN PHARMACEUTICAL R&D INVESTMENTS TO SUPPORT GROWTH
• 11.3 BIOLOGICS
  • 11.3.1 MONOCLONAL ANTIBODIES
    • 11.3.1.1 Surging demand for targeted therapies across oncology, autoimmune disorders, and infectious diseases to drive market
  • 11.3.2 CELL & GENE THERAPY
    • 11.3.2.1 Robust pipeline and R&D initiatives to drive market
  • 11.3.3 OTHER BIOLOGICS
• 11.4 MEDICAL DEVICES
  • 11.4.1 RAPID INNOVATIONS IN DIAGNOSTICS, IMPLANTABLES, AND DIGITAL HEALTH TECHNOLOGIES TO FOSTER GROWTH
• 11.5 BIOSIMILARS
  • 11.5.1 MONOCLONAL ANTIBODY BIOSIMILARS
    • 11.5.1.1 Rising demand for affordable therapeutic options to support growth
  • 11.5.2 INSULIN
    • 11.5.2.1 Increasing patent expirations to contribute to growth
  • 11.5.3 COLONY-STIMULATING FACTORS
    • 11.5.3.1 Increasing use of colony-stimulating factor during post-chemotherapy to aid growth
  • 11.5.4 ERYTHROPOIETIN
    • 11.5.4.1 Essential role of erythropoietin in treating anemia to stimulate growth
  • 11.5.5 OTHER BIOSIMILARS

12 CRO SERVICES MARKET, BY THERAPEUTIC AREA

• 12.1 INTRODUCTION
• 12.2 ONCOLOGY
  • 12.2.1 GROWING INCIDENCE OF CANCER TO DRIVE MARKET
  • 12.2.2 BREAST CANCER
    • 12.2.2.1 Increasing cases and high spending on treating breast cancer to support growth
  • 12.2.3 LUNG CANCER
    • 12.2.3.1 Increasing focus on developing drugs against lung cancer to foster growth
  • 12.2.4 COLORECTAL CANCER
    • 12.2.4.1 Increasing drug discovery and development efforts against colorectal cancer to aid growth
  • 12.2.5 PROSTATE CANCER
    • 12.2.5.1 Growing clinical pipeline to propel market
  • 12.2.6 OTHER CANCERS
• 12.3 INFECTIOUS DISEASES
  • 12.3.1 INCREASING INCIDENCE OF CHRONIC INFECTIONS TO SUPPORT GROWTH
• 12.4 CARDIOVASCULAR SYSTEM DISORDERS
  • 12.4.1 HIGH MORTALITY RATES OF CARDIOVASCULAR DISEASES TO FUEL MARKET
• 12.5 NEUROLOGY
  • 12.5.1 GROWING INVESTMENTS IN NEUROLOGICAL DISORDER RESEARCH TO DRIVE MARKET
• 12.6 VACCINES
  • 12.6.1 INCREASING FOCUS ON VACCINE DEVELOPMENT TO SPUR GROWTH
• 12.7 METABOLIC DISORDERS/ENDOCRINOLOGY
  • 12.7.1 INCREASING GLOBAL DIABETES AND OBESITY POPULATION TO PROMOTE GROWTH
• 12.8 IMMUNOLOGICAL DISORDERS
  • 12.8.1 GROWING CLINICAL RESEARCH FOR IMMUNOLOGICAL DISORDERS TO BOOST MARKET
• 12.9 PSYCHIATRY
  • 12.9.1 RISING CASES OF PSYCHIATRIC DISORDERS AND DEPRESSION TO SUSTAIN GROWTH
• 12.10 RESPIRATORY DISORDERS
  • 12.10.1 RISING INCIDENCE OF CHRONIC RESPIRATORY DISEASE TO FOSTER GROWTH
• 12.11 DERMATOLOGY
  • 12.11.1 GROWING FOCUS ON DRUG DEVELOPMENT AGAINST VARIOUS SKIN CONDITIONS TO DRIVE MARKET
• 12.12 OPHTHALMOLOGY
  • 12.12.1 GROWTH IN NUMBER OF OPHTHALMOLOGY PIPELINE DRUGS TO SUPPORT SEGMENT GROWTH
• 12.13 GASTROINTESTINAL DISEASES
  • 12.13.1 RAPID LIFESTYLE AND DIETARY CHANGES TO AMPLIFY GROWTH
• 12.14 GENITOURINARY & WOMEN'S HEALTH
  • 12.14.1 RISING AWARENESS ABOUT EARLY DISEASE DIAGNOSIS AND TREATMENT TO BOLSTER MARKET
• 12.15 HEMATOLOGY
  • 12.15.1 INCREASING DRUG APPROVALS FOR DRUGS AGAINST NON-MALIGNANT HEMATOLOGICAL CONDITIONS TO SUPPORT GROWTH
• 12.16 OTHER THERAPEUTIC AREAS

13 CRO SERVICES MARKET, BY END USER

• 13.1 INTRODUCTION
• 13.2 PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
  • 13.2.1 INCREASING OUTSOURCING AND PARTNERSHIPS TO ACCELERATE GROWTH
  • 13.2.2 LARGE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
    • 13.2.2.1 Demand for therapeutic expertise and global reach to aid outsourcing to CROs
  • 13.2.3 SMALL & MID-SIZE PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES
    • 13.2.3.1 Demand is driven by need to control fixed costs, access global development expertise, and accelerate timelines
• 13.3 MEDICAL DEVICE COMPANIES
  • 13.3.1 INCREASING GROWTH INITIATIVES BY MEDTECH CROS TO DRIVE MARKET
• 13.4 ACADEMIC INSTITUTES
  • 13.4.1 CONSISTENT COLLABORATIONS BETWEEN CROS AND ACADEMIA TO INTENSIFY GROWTH

14 CRO SERVICES MARKET, BY REGION

• 14.1 INTRODUCTION
• 14.2 NORTH AMERICA
  • 14.2.1 US
    • 14.2.1.1 Increasing incidence of oncology indications to accelerate growth
  • 14.2.2 CANADA
    • 14.2.2.1 Favorable government initiatives and high investments to support growth
• 14.3 EUROPE
  • 14.3.1 GERMANY
    • 14.3.1.1 Presence of strong pharmaceutical and biotechnology R&D infrastructure to spur growth
  • 14.3.2 UK
    • 14.3.2.1 Rising pharmaceutical R&D expenditure to expedite growth
  • 14.3.3 FRANCE
    • 14.3.3.1 Increasing technological advancements and faster drug discovery and development initiatives to aid growth
  • 14.3.4 ITALY
    • 14.3.4.1 Short timeline for drug approvals to encourage growth
  • 14.3.5 SPAIN
    • 14.3.5.1 Growing investment in pharmaceutical industry to boost market
  • 14.3.6 REST OF EUROPE
• 14.4 ASIA PACIFIC
  • 14.4.1 CHINA
    • 14.4.1.1 Continued efforts on improving the level of drug safety and supply to spur growth
  • 14.4.2 INDIA
    • 14.4.2.1 Large pool of patients and presence of highly skilled medical professionals to augment growth
  • 14.4.3 JAPAN
    • 14.4.3.1 Growing drug development activity to propel market
  • 14.4.4 AUSTRALIA
    • 14.4.4.1 Growing focus on funding opportunities to propel market
  • 14.4.5 SOUTH KOREA
    • 14.4.5.1 Emerging clinical research hub to sustain growth
  • 14.4.6 REST OF ASIA PACIFIC
• 14.5 LATIN AMERICA
  • 14.5.1 BRAZIL
    • 14.5.1.1 Growing focus on enhancing pharmaceutical research and production to fuel market
  • 14.5.2 MEXICO
    • 14.5.2.1 Increasing investments in pharma R&D to promote growth
  • 14.5.3 REST OF LATIN AMERICA
• 14.6 MIDDLE EAST
  • 14.6.1 GCC COUNTRIES
    • 14.6.1.1 Kingdom of Saudi Arabia (KSA)
      • 14.6.1.1.1 Expanding clinical trials ecosystem to contribute to growth
    • 14.6.1.2 United Arab Emirates (UAE)
      • 14.6.1.2.1 Growing clinical trials activity to drive market
    • 14.6.1.3 Rest of GCC Countries
  • 14.6.2 REST OF MIDDLE EAST
• 14.7 AFRICA
  • 14.7.1 BOOMING PHARMACEUTICAL INDUSTRY TO FACILITATE GROWTH

15 COMPETITIVE LANDSCAPE

• 15.1 INTRODUCTION
• 15.2 KEY PLAYER STRATEGIES/RIGHT TO WIN
  • 15.2.1 OVERVIEW OF STRATEGIES ADOPTED BY KEY PLAYERS IN CRO SERVICES MARKET, JANUARY 2023-MARCH 2026
• 15.3 REVENUE ANALYSIS, 2021-2025
• 15.4 MARKET SHARE ANALYSIS, 2025
• 15.5 COMPANY EVALUATION MATRIX: KEY PLAYERS, 2025
  • 15.5.1 STARS
  • 15.5.2 EMERGING LEADERS
  • 15.5.3 PERVASIVE PLAYERS
  • 15.5.4 PARTICIPANTS
  • 15.5.5 COMPANY FOOTPRINT: KEY PLAYERS, 2025
    • 15.5.5.1 Company footprint
    • 15.5.5.2 Region footprint
    • 15.5.5.3 Type footprint
• 15.6 COMPANY EVALUATION MATRIX: STARTUPS/SMES, 2025
  • 15.6.1 PROGRESSIVE COMPANIES
  • 15.6.2 RESPONSIVE COMPANIES
  • 15.6.3 DYNAMIC COMPANIES
  • 15.6.4 STARTING BLOCKS
  • 15.6.5 COMPETITIVE BENCHMARKING
    • 15.6.5.1 Detailed list of key startups/SMEs
    • 15.6.5.2 Competitive benchmarking of startups/SMEs
• 15.7 COMPANY VALUATION & FINANCIAL METRICS
  • 15.7.1 FINANCIAL METRICS
  • 15.7.2 COMPANY VALUATION
• 15.8 SERVICE COMPARISON
• 15.9 COMPETITIVE SCENARIO
  • 15.9.1 SERVICE LAUNCHES & APPROVALS
  • 15.9.2 DEALS
  • 15.9.3 EXPANSIONS

16 COMPANY PROFILES

• 16.1 KEY PLAYERS
  • 16.1.1 IQVIA INC.
    • 16.1.1.1 Business overview
    • 16.1.1.2 Services/Solutions offered
    • 16.1.1.3 Recent developments
      • 16.1.1.3.1 Product & service launches
      • 16.1.1.3.2 Deals
    • 16.1.1.4 MnM view
      • 16.1.1.4.1 Key strengths/Right to win
      • 16.1.1.4.2 Strategic choices made
      • 16.1.1.4.3 Weaknesses and competitive threats
  • 16.1.2 ICON PLC
    • 16.1.2.1 Business overview
    • 16.1.2.2 Services/Solutions offered
    • 16.1.2.3 Recent developments
      • 16.1.2.3.1 Service launches
      • 16.1.2.3.2 Deals
      • 16.1.2.3.3 Expansions
    • 16.1.2.4 MnM view
      • 16.1.2.4.1 Key strengths/Right to win
      • 16.1.2.4.2 Strategic choices made
      • 16.1.2.4.3 Weaknesses and competitive threats
  • 16.1.3 THERMO FISHER SCIENTIFIC INC.
    • 16.1.3.1 Business overview
    • 16.1.3.2 Services/Solutions offered
    • 16.1.3.3 Recent developments
      • 16.1.3.3.1 Service launches
      • 16.1.3.3.2 Deals
      • 16.1.3.3.3 Expansions
    • 16.1.3.4 MnM view
      • 16.1.3.4.1 Key strengths/Right to win
      • 16.1.3.4.2 Strategic choices made
      • 16.1.3.4.3 Weaknesses and competitive threats
  • 16.1.4 LABORATORY CORPORATION OF AMERICA HOLDINGS
    • 16.1.4.1 Business overview
    • 16.1.4.2 Services/Solutions offered
    • 16.1.4.3 Recent developments
      • 16.1.4.3.1 Service launches
      • 16.1.4.3.2 Deals
      • 16.1.4.3.3 Expansions
      • 16.1.4.3.4 Other developments
    • 16.1.4.4 MnM view
      • 16.1.4.4.1 Key strengths/Right to win
      • 16.1.4.4.2 Strategic choices made
      • 16.1.4.4.3 Weaknesses and competitive threats
  • 16.1.5 FORTREA, INC.
    • 16.1.5.1 Company overview
    • 16.1.5.2 Services/Solutions offered
    • 16.1.5.3 Recent developments
      • 16.1.5.3.1 Service launches
      • 16.1.5.3.2 Deals
      • 16.1.5.3.3 Expansions
      • 16.1.5.3.4 Other developments
    • 16.1.5.4 MnM view
      • 16.1.5.4.1 Key strengths/Right to win
      • 16.1.5.4.2 Strategic choices made
      • 16.1.5.4.3 Weaknesses and competitive threats
  • 16.1.6 SYNEOS HEALTH
    • 16.1.6.1 Business overview
    • 16.1.6.2 Services/Solutions offered
    • 16.1.6.3 Recent developments
      • 16.1.6.3.1 Service launches
      • 16.1.6.3.2 Deals
  • 16.1.7 WUXI APPTEC
    • 16.1.7.1 Business overview
    • 16.1.7.2 Services/Solutions offered
    • 16.1.7.3 Recent developments
      • 16.1.7.3.1 Expansions
      • 16.1.7.3.2 Other developments
  • 16.1.8 CHARLES RIVER LABORATORIES
    • 16.1.8.1 Business overview
    • 16.1.8.2 Services/Solutions offered
    • 16.1.8.3 Recent developments
      • 16.1.8.3.1 Deals
  • 16.1.9 PAREXEL INTERNATIONAL CORPORATION
    • 16.1.9.1 Business overview
    • 16.1.9.2 Services/Solutions offered
    • 16.1.9.3 Recent developments
      • 16.1.9.3.1 Deals
      • 16.1.9.3.2 Expansions
  • 16.1.10 PHARMARON
    • 16.1.10.1 Business overview
    • 16.1.10.2 Services/Solutions offered
  • 16.1.11 MEDPACE
    • 16.1.11.1 Business overview
    • 16.1.11.2 Services/Solutions offered
  • 16.1.12 SGS SA
    • 16.1.12.1 Business overview
    • 16.1.12.2 Services/Solutions offered
    • 16.1.12.3 Recent developments
      • 16.1.12.3.1 Deals
  • 16.1.13 FRONTAGE LABS
    • 16.1.13.1 Business overview
    • 16.1.13.2 Services/Solutions offered
    • 16.1.13.3 Recent developments
      • 16.1.13.3.1 Deals
      • 16.1.13.3.2 Other developments
  • 16.1.14 EUROFINS SCIENTIFIC
    • 16.1.14.1 Business overview
    • 16.1.14.2 Services/Solutions offered
  • 16.1.15 TIGERMED
    • 16.1.15.1 Business overview
    • 16.1.15.2 Services offered
    • 16.1.15.3 Recent developments
      • 16.1.15.3.1 Product/Service approvals
      • 16.1.15.3.2 Deals
  • 16.1.16 PSI CRO AG
    • 16.1.16.1 Business overview
    • 16.1.16.2 Services/Solutions offered
    • 16.1.16.3 Recent developments
      • 16.1.16.3.1 Service launches
      • 16.1.16.3.2 Deals
      • 16.1.16.3.3 Expansions
  • 16.1.17 BIOAGILE
    • 16.1.17.1 Business overview
    • 16.1.17.2 Services/Solutions offered
  • 16.1.18 FIRMA CLINICAL RESEARCH
    • 16.1.18.1 Business overview
    • 16.1.18.2 Services/Solutions offered
  • 16.1.19 ACCULAB LIFE SCIENCES
    • 16.1.19.1 Business overview
    • 16.1.19.2 Services/Solutions offered
  • 16.1.20 NOVOTECH
    • 16.1.20.1 Business overview
    • 16.1.20.2 Services/Solutions offered
    • 16.1.20.3 Recent developments
      • 16.1.20.3.1 Deals
  • 16.1.21 LINICAL
    • 16.1.21.1 Business overview
    • 16.1.21.2 Services/Solutions offered
    • 16.1.21.3 Recent developments
      • 16.1.21.3.1 Expansions
  • 16.1.22 ADVANCED CLINICAL
    • 16.1.22.1 Business overview
    • 16.1.22.2 Services/Solutions offered
    • 16.1.22.3 Recent developments
      • 16.1.22.3.1 Deals
• 16.2 OTHER PLAYERS
  • 16.2.1 ALLUCENT
  • 16.2.2 EMVENIO
  • 16.2.3 GUIRES INC. (PEPGRA HEALTHCARE PVT. LTD.)
  • 16.2.4 WORLDWIDE CLINICAL TRIALS
  • 16.2.5 CTI CLINICAL TRIAL & CONSULTING

17 RESEARCH METHODOLOGY

• 17.1 RESEARCH APPROACH
  • 17.1.1 SECONDARY DATA
    • 17.1.1.1 Key sources of secondary data
    • 17.1.1.2 Key objectives of secondary research
  • 17.1.2 PRIMARY DATA
    • 17.1.2.1 Breakdown of primaries
    • 17.1.2.2 Key objectives of primary research
• 17.2 MARKET ESTIMATION METHODOLOGY
  • 17.2.1 COMPANY REVENUE ANALYSIS (BOTTOM-UP APPROACH)
  • 17.2.2 MNM REPOSITORY ANALYSIS AND PRIMARY RESEARCH
  • 17.2.3 SEGMENTAL MARKET ASSESSMENT (TOP-DOWN APPROACH)
• 17.3 GROWTH RATE PROJECTIONS
• 17.4 DATA TRIANGULATION
• 17.5 RESEARCH ASSUMPTIONS
• 17.6 RESEARCH LIMITATIONS
• 17.7 RISK ANALYSIS

18 APPENDIX

• 18.1 DISCUSSION GUIDE
• 18.2 KNOWLEDGESTORE: MARKETSANDMARKETS' SUBSCRIPTION PORTAL
• 18.3 CUSTOMIZATION OPTIONS
• 18.4 RELATED REPORTS
• 18.5 AUTHOR DETAILS